Sangamo Therapeutics Stock Probability of Future Stock Price Finishing Over 31.11

SGMO Stock  USD 2.47  0.16  6.93%   
Sangamo Therapeutics' future price is the expected price of Sangamo Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Sangamo Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Sangamo Therapeutics Backtesting, Sangamo Therapeutics Valuation, Sangamo Therapeutics Correlation, Sangamo Therapeutics Hype Analysis, Sangamo Therapeutics Volatility, Sangamo Therapeutics History as well as Sangamo Therapeutics Performance.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
  
As of the 22nd of December 2024, Price To Sales Ratio is likely to drop to 0.51. In addition to that, Price Earnings Ratio is likely to drop to -0.39. Please specify Sangamo Therapeutics' target price for which you would like Sangamo Therapeutics odds to be computed.

Sangamo Therapeutics Target Price Odds to finish over 31.11

The tendency of Sangamo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 31.11  or more in 90 days
 2.47 90 days 31.11 
close to zero percent
Based on a normal probability distribution, the odds of Sangamo Therapeutics to move over $ 31.11  or more in 90 days from now is close to zero percent (This Sangamo Therapeutics probability density function shows the probability of Sangamo Stock to fall within a particular range of prices over 90 days) . Probability of Sangamo Therapeutics price to stay between its current price of $ 2.47  and $ 31.11  at the end of the 90-day period is about 11.57 .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.38 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Sangamo Therapeutics will likely underperform. Moreover Sangamo Therapeutics has an alpha of 1.9154, implying that it can generate a 1.92 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Sangamo Therapeutics Price Density   
       Price  

Predictive Modules for Sangamo Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sangamo Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.112.2512.42
Details
Intrinsic
Valuation
LowRealHigh
0.173.4013.57
Details
Naive
Forecast
LowNextHigh
0.062.8212.99
Details
8 Analysts
Consensus
LowTargetHigh
5.996.587.30
Details

Sangamo Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Sangamo Therapeutics is not an exception. The market had few large corrections towards the Sangamo Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sangamo Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sangamo Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.92
β
Beta against Dow Jones3.38
σ
Overall volatility
0.66
Ir
Information ratio 0.19

Sangamo Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sangamo Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sangamo Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sangamo Therapeutics is way too risky over 90 days horizon
Sangamo Therapeutics appears to be risky and price may revert if volatility continues
Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M).
Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02.
Sangamo Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from thelincolnianonline.com: Sangamo Therapeutics Receives Buy Rating from HC Wainwright

Sangamo Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sangamo Stock often depends not only on the future outlook of the current and potential Sangamo Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sangamo Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding174.4 M
Cash And Short Term Investments81 M

Sangamo Therapeutics Technical Analysis

Sangamo Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Sangamo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Sangamo Therapeutics. In general, you should focus on analyzing Sangamo Stock price patterns and their correlations with different microeconomic environments and drivers.

Sangamo Therapeutics Predictive Forecast Models

Sangamo Therapeutics' time-series forecasting models is one of many Sangamo Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Sangamo Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Sangamo Therapeutics

Checking the ongoing alerts about Sangamo Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Sangamo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sangamo Therapeutics is way too risky over 90 days horizon
Sangamo Therapeutics appears to be risky and price may revert if volatility continues
Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M).
Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02.
Sangamo Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from thelincolnianonline.com: Sangamo Therapeutics Receives Buy Rating from HC Wainwright
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.